12451366

Source:http://linkedlifedata.com/resource/pubmed/id/12451366

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0006050, umls-concept:C0016504, umls-concept:C0030705, umls-concept:C0034656, umls-concept:C0178602, umls-concept:C0238767, umls-concept:C0326391, umls-concept:C1696465, umls-concept:C1707455
pubmed:dateCreated	2002-11-26
pubmed:abstractText	Optimum dosing for botulinum toxin type A (BTX-A) in crow's feet remains to be defined.
pubmed:language	eng
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Botulinum Toxins, Type A, http://linkedlifedata.com/resource/pubmed/chemical/Neuromuscular Agents
pubmed:status	MEDLINE
pubmed:author	pubmed-author:LaskGaryG, pubmed-author:LoweNicholas JNJ, pubmed-author:MooreDonnaD, pubmed-author:YamauchiPaulP
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	834-40
pubmed:dateRevised	2010-11-18
pubmed:articleTitle	Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet.
pubmed:affiliation	Clinical Research Specialists, Santa Monica, CA 90404, USA. cranleyuk@aol.com